Screener
Edgewise Therapeutics, Inc. EWTX EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The source filing: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:09 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056713
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Interest income | 5,102 | 5,161 |
| Total other income | 5,102 | 5,161 |
| Net loss | (49,013) | (40,798) |
| Other comprehensive income (loss): | ||
| Unrealized loss on available-for-sale securities, net | (929) | (19) |
| Total comprehensive loss | $(49,942) | $(40,817) |
| Net loss per share, basic and diluted | $(0.46) | $(0.43) |
| Weighted-average shares outstanding, basic and diluted | 107,116,709 | 95,130,053 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Edgewise Therapeutics, Inc.'s EPS (basic)?
- Edgewise Therapeutics, Inc. (EWTX) reported EPS (basic) of -$0.46 in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s EPS (basic) changed year-over-year?
- Edgewise Therapeutics, Inc.'s EPS (basic) decreased by 7.0% year-over-year, from -$0.43 to -$0.46.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s EPS (basic)?
- Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s EPS (basic) has grown at a -24.6% compound annual growth rate (CAGR), from -$5.08 to -$1.64.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.
Ask your AI about Edgewise Therapeutics, Inc.'s eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude